1. In this randomized controlled trial, for patients with chronic limb-threatening ischemia (CLTI) due to infrapopliteal artery disease (IAD), a drug-eluting resorbable scaffold was superior to angioplasty in reducing the risk of vascular events. 2. There was no significant difference in the adverse events between the drug-eluting resorbable scaffold and angioplasty groups. Evidence Rating Level:
Everolimus-eluting scaffold found better than angioplasty for CLTI patients with infrapopliteal artery disease medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.